Atezolizumab
Tecentriq (atezolizumab) is an antibody pharmaceutical. Atezolizumab was first approved as Tecentriq on 2016-05-18. It is used to treat non-small-cell lung carcinoma and urinary bladder neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, and urologic neoplasms. The pharmaceutical is active against programmed cell death 1 ligand 1.
| Trade Name | Tecentriq |
|---|---|
| Common Name | Atezolizumab |
| Indication | breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, urinary bladder neoplasms, urologic neoplasms |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
